Purpose: Oxazaphosphorines are metabolised by a variety of pathways, o
ne of which leads to activation and the formation of alkylating compou
nds. However, the transport forms conveying activated oxazaphosphorine
s to the tumour cell have not been fully characterised. There is incre
asing recognition of the importance of the erythrocyte as a carrier of
compounds in the circulation, and we have recently described higher c
oncentrations of 4-hydroxycyclophosphamide within the erythrocyte comp
artment compared to plasma. We have now determined the concentrations
of ifosfamide and seven of its metabolites in the plasma and erythrocy
tes of patients receiving a six-hour intravenous infusion of ifosfamid
e.Patients and methods. Red cells from five patients, receiving a tota
l of eight cycles of ifosfamide, were separated from plasma using the
MESED instrument, and analysis of red cells and plasma performed using
Gas Chromatography-Mass Spectrometry (GC/MS). Results: The concentrat
ion of all compounds in the erythrocyte compartment was higher than or
equal to those in plasma, and isophosphoramide mustard and carboxyifo
sfamide showed a particular affinity for the erythrocyte. The red cell
fraction can contain as much as 77% of the total blood concentration
of isophosphoramide mustard. Conclusions: Erythrocyte associated isoph
osphoramide mustard is an important transport form of activated ifosfa
mide. Red cells may have a role in the delivery of activated oxazaphos
phorines to tissues.